Background {#Sec1}
==========

Coronaviruses (CoVs) are one of the major pathogens that are grouped in the family of Coronaviridae, which primarily target the human respiratory system \[[@CR1]\]. It is one of the emerging and reemerging viral outbreaks throughout the world. Previous outbreaks of coronaviruses include the severe acute respiratory syndrome (SARS)-CoV epidemic in 2003 \[[@CR2]\] and the Middle East respiratory syndrome (MERS)-CoV in 2012 \[[@CR3]\], while the newly emergent coronavirus, initially referred to as 2019-nCoV and subsequently termed SARS-CoV-2, the disease it produces has been termed COVID-19, which causes respiratory infection and can progress to severe pneumonia and, in a small number of cases, death \[[@CR4]\]. Although these coronaviruses were isolated from different human and animal hosts at different times and locations, they all belong to the species severe acute respiratory syndrome-related coronavirus \[[@CR5], [@CR6]\].

The increasing mortality rate warrants that vulnerable populations in the society be identified and protected. When COVID-19 and other CoV infect women who are pregnant, it increases the risk of adverse obstetrical and neonatal outcomes and results in severe respiratory disease \[[@CR5]\]. Previous data from multiple studies of influenza and other respiratory infectious diseases have demonstrated an increased risk of maternal obstetrical complications when compared with nonpregnant women due to physiological changes occurring during pregnancy \[[@CR7]\]. This association has also been previously demonstrated to occur when pregnant women became infected with either of the two pathogenic coronavirus infections (SARS-CoV 2 and MERS-CoV) \[[@CR8]\].

Coronavirus infection in pregnant women makes clinical management more difficult by prolonging and complicating the illness and compromises the treatment \[[@CR9]\]. Researchers are still in question regarding the transmission of the novel and previous coronavirus infection from a pregnant woman to her fetus, a process termed vertical transmission \[[@CR10]--[@CR12]\]. There are few published cases of coronavirus disease occurring during pregnancy and due to the possibility of mother--fetal vertical transmission, there is a concern that the fetuses may be at risk of congenital COVID-19 and other CoV outbreaks. Due to the alarming spread of CoV outbreaks throughout the world, a comprehensive understanding of the transmission of the virus from mother to fetus in utero like other emerging viral infections as Zika virus and Ebola virus \[[@CR13], [@CR14]\], that can threaten the health and survival of an infected mother and fetus is essential for effective management of the infection and treatment. Therefore, this systematic review and meta-analysis was aimed to assess the effect of coronavirus infection (SARS-CoV-2, MERS-CoV, and SARS-CoV) during pregnancy and its possibility of vertical maternal--fetal transmission.

Methods {#Sec2}
=======

Study design {#Sec3}
------------

A systematic review and meta-analysis was aimed to assess the effect of coronavirus infection (SARS-CoV-2, MERS-CoV, and SARS-CoV) during pregnancy and its possibility of vertical maternal--fetal transmission following the methodological framework suggested by Arksey and O'Malley \[[@CR15]\].

Search strategies {#Sec4}
-----------------

All relevant articles were searched without date limits using the following databases: PubMed, Web science, Embase, Google Scholar, Cochrane library, and Science Direct according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) \[[@CR16]\]. All searches were limited to article written in English given that such language restriction does not alter the outcome of the systematic reviews and meta-analysis \[[@CR17]\]. The gray literature of observational studies was searched through the review of reference lists and input of content experts. We searched scientific publications from 2003 to 2020. All papers published until the end of April 30, 2020, and fulfill the inclusion criteria were considered. The search used the following keywords: coronavirus, novel coronavirus-2019 infection, pregnancy, Middle East respiratory syndrome, severe acute respiratory syndrome, severe acute respiratory syndrome coronavirus-2, and vertical transmission. We searched all terms with the help of Boolean operators like "AND" or "OR".

Eligibility criteria {#Sec5}
--------------------

All articles with a report of pregnant women with confirmed severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), Middle East respiratory syndrome coronavirus (MERS-CoV) or severe acute respiratory syndrome coronavirus (SARS-CoV) and other related illness with different clinical features published in English from 2003 to April 30/2020 were included in the study. Case studies and case series reported pregnant women with confirmed coronavirus; other clinical features were included with caution. Studies pertaining to other coronavirus-related illnesses, studies that were not fully accessible, and duplicate publications of the same study were excluded.

Assessment of study quality {#Sec6}
---------------------------

Studies selected for inclusion were assessed for methodological quality by all authors' independently using the standard critical appraisal instruments of the Joanna Briggs Institute Meta-Analysis of Statistics Assessment Review Instrument (JBI-MAStARI) \[[@CR18]\]. The disagreements were resolved by consensus.

Outcome measures {#Sec7}
----------------

The primary outcome variable of this study was the pregnancy outcomes observed, listed as follows: preterm birth (PTB; either before 37 or 34 weeks of gestation), preeclampsia, preterm prelabor rupture of membranes, (pPROM), fetal growth restriction (FGR), miscarriage, maternal death, mode of delivery and other clinical feature, laboratory findings and coexisting disease. The secondary outcomes were the perinatal outcomes observed as listed: fetal distress, apgar score \< 7 at 5 min, neonatal asphyxia, admission to the neonatal intensive care unit (NICU), perinatal death, including both stillbirth, and neonatal death, evidence in utero transmission.

Data extraction and synthesis {#Sec8}
-----------------------------

The data were extracted using a standardized data extraction format, adapted from the Joanna Briggs Institute (JBI), by three authors (KD, EA, and AG), independently extracting all necessary data using an excel spreadsheet form. Then the extracted data were merged for systematic analysis. Any disagreements during the data extraction were resolved through discussion and consensus. The main outcomes extracted from the study were: primary author, study design, publication year, country, patient demographics, maternal and perinatal outcome, and evidence of in utero transmission of coronavirus. All clinical characteristics of pregnant women infected with coronavirus, laboratory and radiological findings, treatment options, and data on associated risk factors were extracted by the authors.

Statistical analysis {#Sec9}
--------------------

Following data extraction, systematic review and meta-analysis were carried out using R software version 3.6.1 and STATA statistical software (version 13) with user-contributed commands for meta-analyses: metaprop, metan, metainf, metabias, and metareg \[[@CR19]\]. The effect sizes and SEs of the studies were pooled using a random-effects model to calculate the pooled estimates of laboratory findings, other clinical features and coexisting diseases among patients with COVID-19 infection. A meta-analysis was also planned to assess the association of various comorbidities and laboratory findings with the severity of disease.

Risk of bias and sensitivity analysis {#Sec10}
-------------------------------------

The standard error for each original study was calculated using the binomial distribution formula. Evidence for statistical heterogeneity among reported prevalence was using the Cochrane *Q*-test and *I*^2^ statics \[[@CR20]\]. The pooled proportion was estimated by using the back-transform of the weighted mean of the transformed proportions for both the fixed-effects model and the random-effects model \[[@CR21]\]. A significance level of *P* \< 0.10 and *I*^2^ \> 50% was interpreted as evidence of heterogeneity \[[@CR22], [@CR23]\]. A potential source of heterogeneity was investigated by subgroup analysis and meta-regression analysis \[[@CR24]\]. Where statistical pooling was not possible, the findings were presented in a narrative form including tables and figures to aid in data presentation where appropriate.

Sensitivity analyses were conducted to weigh up the relative influence of each individual study on the pooled effect size using a user-written function, metainf. The presence of publication bias was assessed informally by visual inspection of funnel plots \[[@CR25]\]. Point prevalence, as well as 95% confidence intervals, was presented in the forest plot format.

Results {#Sec11}
=======

Study selection {#Sec12}
---------------

Database searches identified a total of 879 articles. From these initial articles, 29 articles were excluded due to duplication. From the remaining 850 articles, 786 articles were excluded after review of their titles and abstracts confirmed nonrelevance to this review. Therefore, 64 full-text articles were assessed for eligibility based on the preset criteria, which resulted in the further exclusion of 25 articles primarily due to the outcome of the interest being not reported in the study. Ultimately, 39 studies met the eligibility criteria and were included in the final review (Fig. [1](#Fig1){ref-type="fig"} and Table [1](#Tab1){ref-type="table"}).Fig. 1Flowchart of study selection for systematic review and meta-analysis of pregnant women with laboratory-confirmed coronavirus infectionTable 1Review of studies reporting coronavirus infection in pregnant womenAuthorYearStudy areaTest designPregnancy (*n*)Age groupVirus detected in motherSevere cases *n* (%)Chen \[[@CR12]\]2020ChinaRetrospective926--40SARS-CoV-20 (0%)Zhu \[[@CR26]\]2020WuhanRetrospective925--35SARS-CoV-22 (22.2%)Penfield \[[@CR27]\]2020New YorkRetrospective1122--40SARS-CoV-25 (45.5%)Liu \[[@CR28]\]2020WuhanCase series330--34SARS-CoV-23 (100%)Yan \[[@CR29]\]2020ChinaRetrospective6524--40SARS-CoV-28 (12.5%)Zhang \[[@CR30]\]2020WuhanRetrospective1624--34SARS-CoV-21 (6.3%)Pierce \[[@CR31]\]2020USCohort study64n/aSARS-CoV-264 (100%)Chen \[[@CR32]\]2020WuhanCross-sectional525--30SARS-CoV-20 (0%)Dong \[[@CR33]\]2020WuhanCase report129SARS-CoV-21 (100%)Fan \[[@CR34]\]2020WuhanCase report229,34SARS-CoV-2n/aYang \[[@CR35]\]2020WuhanCross-sectional7n/aSARS-CoV-2n/aLi \[[@CR36]\]2020ChinaCase report130SARS-CoV-20 (0%)Wang \[[@CR37]\]2020ChinaCase report128SARS-CoV-2n/aCui \[[@CR38]\]2020ChinaCase report155SARS-CoV-21 (100%)Yu \[[@CR39]\]2020WuhanRetrospective729--34SARS-CoV-20 (0%)Zeng \[[@CR40]\]2020WuhanCohort study33n/aSARS-CoV-2n/aBreslin \[[@CR41]\]2020New YorkRetrospective4320--39SARS-CoV-26 (14.0%)Liu \[[@CR42]\]2020ChinaRetrospective1324--36SARS-CoV-22 (15.4%)Liu \[[@CR43]\]2020WuhanRetrospective1523--40SARS-CoV-2n/aLiu \[[@CR44]\]2020ShanghaiRetrospective1622--42SARS-CoV-2n/aLiu \[[@CR45]\]2020WuhanCross-sectional1027--34SARS-CoV-2n/aKnight \[[@CR46]\]2020UKProspective427n/aSARS-CoV-240Lokken \[[@CR47]\]2020USARetrospective4626--34SARS-CoV-2n/aLumbreras \[[@CR48]\]2020MexicoRetrospective30826--39SARS-CoV-2n/aAndrikopoulou \[[@CR49]\]2020NewYorkCase series158n/aSARS-CoV-234MERS-CoV Assiri \[[@CR50]\]2016SACase series515--45MERS-C0V5 (100%) Alfaraj \[[@CR51]\]2019SACase series229, 39MERS-C0V0 Jeong \[[@CR52]\]2017SKCase report139MERS-C0V0 Park \[[@CR53]\]2016SKCase report139MERS-C0V1 (100%) Malik \[[@CR54]\]2016UAECase report132MERS-C0V1 (100%) Payne \[[@CR55]\]2014JordanCase report139MERS-C0V0 Alserehi \[[@CR56]\]2016SACase report133MERS-C0V1 (100%)SARS-CoV Robertson \[[@CR57]\]2004USACase report136SARS-CoV1 (100%) Stockman \[[@CR58]\]2004USACase report138SARS-CoV0 Lam \[[@CR59]\]2004ChinaCase control1025--37SARS-CoV6 (60%) Wong \[[@CR60]\]2004ChinaRetrospective1224--44SARS-CoV6 (50%) Schneider \[[@CR61]\]2004USACase report1--SARS-CoV0 Ng \[[@CR62]\]2006ChinaRetrospective725--34SARS-CoV3 (42.9%) Yudin \[[@CR63]\]2005CanadaCase report133SARS-CoV0

Description of included studies {#Sec13}
-------------------------------

In the current review, 39 articles with a total of 1316 pregnant women with laboratory-confirmed CoV \[[@CR12], [@CR26]--[@CR49]\] infection \[1271 with SARS-CoV-2 \[[@CR12], [@CR26]--[@CR49]\], 12 with MERS-CoV \[[@CR50]--[@CR56]\] and 33 with SARS-CoV \[[@CR57]--[@CR63]\] (Table [1](#Tab1){ref-type="table"})\] and reported different maternal and perinatal outcome were included in this study. Most of the studies included in this review were retrospective studies and case series as listed in Table [1](#Tab1){ref-type="table"}. The number of pregnant women confirmed to be infected with SARS-CoV-2, MERS-CoV, and SARS-CoV in different studies ranged from 1 to 427. Majority of the studies that fulfill the inclusion criteria were from China (Table [1](#Tab1){ref-type="table"}). The mean age of the study participants was 33.2 years with a standard deviation of 8.3 years. Out of the 39 studies, 30 papers reported severe disease among pregnant women with a prevalence of SARS-CoV-2 \[20.1% (167/833)\], MERS-CoV \[66.7% (8/12)\] and SARS-CoV \[48.5% (16/33)\] (Table [1](#Tab1){ref-type="table"}).

Commonly reported clinical feature and laboratory finding of pregnant women infected with coronaviruses (SARS-CoV-2, MERS-CoV, and SARS-CoV) {#Sec14}
--------------------------------------------------------------------------------------------------------------------------------------------

From the total of 39 included studies, only 32 studies with a total of 914 pregnant women infected with coronavirus had reported different clinical features. Meta-analysis was performed for those different clinical features of pregnant women infected with coronavirus with available data. According to the report of 39 studies, fever, cough, and fatigue were the most common clinical features of coronavirus-infected pregnant women with prevalence ranged from 30 to 67% in SARS-CoV-2, 50--78% in MERS-CoV and 80--97% in SARS-CoV. The pooled prevalence of all clinical symptoms was 26% with 95% CI (15.2--40.1). Pneumonia was the most diagnosed clinical symptom among pregnant women in the three coronavirus infections with a prevalence of 71.2% in SARS-CoV-2, 71.4% in MERS-CoV and 88.9% in SARS-CoV (Table [2](#Tab2){ref-type="table"}). Among the most commonly reported laboratory findings, lymphocytopenia was the most frequently reported in the three coronavirus infections with prevalence ranged from 63 to 100%, followed by elevated C-reactive protein and leukopenia with prevalence ranged from 45 to 100% (Table [2](#Tab2){ref-type="table"}).Table 2Pooled prevalence of clinical features and laboratory findings of pregnant women with coronavirus infection in the present systematic review and meta-analysisClinical feature of patients with CoV infectionSARS-CoV-2MERS-CoVSARS-CoVStudy (*n*)Reports (*n*)Pregnancies (*n*)Pooled % (95%-CI)Study (*n*)Reports (*n*)Pregnancies (*n*)Pooled % (95%-CI)Study (*n*)Reports (*n*)Pregnancies (*n*)Pooled % (95%-CI)Fever1957587066.1% \[56.1--79.8\]691275% \[30.2--88.9\]7323396.9% \[84.6--100\]Cough1845886952.7% \[34.7--67.7\]47977.8% \[40.1--97.5\]6212680.8% \[61.4--93.6\]Fatigue819263430.3% \[14.4--49.6\]11250% \[1.2--99.2\]--------Dyspnea74930316.2% \[7.6--22.3\]11250% \[1.4--99.6\]191090% \[55.3--100\]Myalgia56129320.8% \[7.5--27.8\]23837.5 \[9.3--76.2\]2162272.7% \[50.1--89.8\]Shortness of Breath618658631.7% \[18.2--41.5\]11250% \[1.4--99.6\]392437.5% \[19.2--59.6\]Sore throat67866811.7% \[5.1--29.1\]--------252222.7% \[8.7--45.5\]Chill3444809.2% \[4.7--71.1\]--------3152365.2% \[43.1--84.8\]Headache58867413.1% \[8.5--33.2\]11250% \[1.4--99.6\]4152462.5% \[41.3--81.9\]Muscle pain36762810.7% \[4.9--25.4\]--------221118.2% \[3.2--35.9\]Diarrhea9417535.4% \[2.2--10.3\]11250% \[1.4--99.6\]232213.6% \[6.6--48.7\]Abdominal pain25647.8% \[3.5--17.1\]11250% \[1.4--99.6\]--------Pneumonia2136851771.2% \[68.6--95.8\]45771.4% \[29.5--96.2\]58988.9% \[52.1--100\]Laboratory finding Leukocytosis6279528.4% \[20.1--39.6\]--------3102441.7% \[22.1--63.2\] Leukopenia6439545.3% \[35.4--56.3\]--------3142458.3% \[37.2--78.3\] Lymphocytosis1287011.4% \[5.5--21.3\]--------432412.5% \[3.2--32.8\] Lymphocytopenia139214663% \[55.7--71.4\]111100% \[3.3--100\]4202483.3% \[63.1--95.5\] ALT↑394818.8% \[9.5--33.7\]21333.3% \[1.6--91.3\]22825% \[3.3--65.3\] AST↑384816.7% \[7.2--30.5\]21333.3% \[1.6--91.3\]22825% \[3.3--65.3\] LDH↑382334.8% \[16.2--57.9\]---------------- C-reactive protein ↑118014355.9% \[47.4--64.2\]111100% \[3.3--100\]111100% \[3.3--100\]*AST* aspartate aminotransferase, *ALT* alanine aminotransferase, *LDH* lactate dehydrogenase

Commonly reported radiological finding and treatment of pregnant women infected with coronaviruses (SARS-CoV-2, MERS-CoV, and SARS-CoV) {#Sec15}
---------------------------------------------------------------------------------------------------------------------------------------

The most common computed tomography imaging features in pregnant women infected with coronaviruses were ground-glass opacity followed by bilateral pneumonia with a prevalence of 65.8% and 57.9%, respectively (Table [3](#Tab3){ref-type="table"}). In this study, ribavirin and oseltamivir were the most commonly used antiviral therapy used for the treatment of viral pathogens among pregnant women infected with coronaviruses with a prevalence of 65.2% and 56.5%, while the most common antibiotic therapy used for the treatment of common bacterial co-infection was azithromycin with prevalence of 35%. In this study, hydroxychloroquine was the leading drug used by people infected with coronaviruses with a prevalence of 79.7%. From the total coronavirus-infected pregnant women, around 78.8% were treated with oxygen therapy while 18.1% were supported by mechanical ventilation (Table [3](#Tab3){ref-type="table"}).Table 3Pooled prevalence of radiological findings and treatment of pregnant women with coronavirus infection in the present systematic review and meta--analysisRadiological finding and treatment of patients with CoV infectionStudy (*n*)Number of reportsPregnancies (*n*)Pooled % (95%-CI)Radiological finding Unilateral pneumonia231520% \[4.4--48.6\] Bilateral pneumonia6111957.9% \[33.5--80.1\] Ground-glass opacity8507665.8% \[54.2--76.4\] Multiple patchy infiltrate552222.7% \[8.9--45.2\]Treatment Oseltamivir6142356.5% \[35.1--64.3\] Remdesivir531618.8% \[13.8--29.1\] Lopinavir221216.7% \[13.1--41.1\] Ritonavir321315.4% \[10.1--31.7\] Ganciclovir721020% \[12.8--44.2\] Ribavirin11152365.2% \[47.3--78.4\] Other antiviral therapy118912869.5% \[39.2--77.8\] Azithromycin472035% \[22.3--48.5\] Other antibiotic therapy1310215764.9% \[60.9--73.1\] Hydroxychloroquine12597479.7% \[70.1--89.3\] Hydrocortisone3112445.8% \[37.2--59.6\] Mechanical ventilation72312718.1% \[12.26.8\] Oxygen therapy98911378.8% \[65.4--89.6\]

The outcome of pregnant women infected with coronavirus and their newborn {#Sec16}
-------------------------------------------------------------------------

Out of 1316 pregnant women infected with CoV, 46.5% give birth at \> 37 weeks of gestation, while the rates of PTB \< 34 and \< 37 weeks of gestation were 9.5% and 14.3%, respectively. Preeclampsia was reported among 5.9% of pregnant women, while the rate of miscarriage for CoV infection was 14.5%. pPROM and FGR were rated 9.2% and 2.8%, respectively. From the total CoV-infected pregnant women, 31.3% were admitted to ICU from which 2.7% were died. The prevalence of cesarean delivery was 56.9%, while 28.6% had undergone normal delivery. Fetal distress was reported in 26.5%, while neonatal asphyxia was reported in only 1.4% of neonates. Only, 1.2% of neonates had apgar score \< 7 at 5 min. Neonate admitted to ICU was rated 11.3%, while the rate of perinatal death was 2.2%. In the current review, none of the studies reported transmission of CoV from the mother to the fetus in utero during the follow-up period (Table [4](#Tab4){ref-type="table"}).Table 4Pooled proportions of the different maternal and postnatal outcomes and coexisting disorder identified in the present systematic reviewPregnancy and perinatal postnatal outcomeStudy (*n*)Number of reportsPregnancies or neonate (*n*)Pooled % (95%--CI)Pregnancy outcome PTB \< 34 week25687199.5% \[7.1--39.5\] PTB \< 37 week229163714.3% \[10.2--30.2\] \> 37 week2533070946.5% \[41.2--56.3\] Pre-eclampsia9101695.9% \[3.6--11.7\] pPROM11171839.3% \[6.6--14.8\] FGR1431082.8% \[1.8--8.9\] Miscarriage496214.5% \[7.7--26.5\] ICU admission296621131.3% \[27.2--55.5\] Maternal death11155572.7% \[1.4--14.6\] Cesarean delivery3244077256.9% \[48.2--78.9\] Normal delivery1719869228.6% \[22.4--41.6\]Prenatal outcome Fetal distress17186826.5% \[17.5--39.5\] Apgar score \< 7161811.2% \[0.0--7.7\] Neonatal asphyxia111711.4% \[0.0--8.9\] Admission to NICU897311.3% \[5.6--20.3\] Perinatal death21104522.2% \[1.2--12.8\] Vertical transmission39013160.0% \[0.0--1.0\]Coexisting disorders Hypertension7819548.5% \[7.1--17.4\] Gestational diabetes9858819.6% \[6.6--20.7\] Cardiovascular disease2274705.7% \[3.0--12.1\] Digestive disease341113.6% \[1.1--9.8\] Asthma4447945.5% \[2.3--36.4\]*PTB* preterm birth, *pPROM* preterm premature rupture of membranes, *FGR* fetal growth restriction, *ICU* intensive care unit, *NICU* neonatal intensive care unit

In our systematic review, different comorbidities that aggravate the infection were found among pregnant women infected with CoV. From the total CoV-infected pregnant women, the rate of gestational diabetes was 9.6%, while hypertension was reported in 8.5% of pregnant women infected with CoV. The rate of asthma in pregnant women infected with CoV was 5.5%, while cardiovascular disease and digestive disease rated 5.7% and 3.6%, respectively (Table [4](#Tab4){ref-type="table"}).

Comparison of severe cases among coronavirus infection (SARS-CoV-2, MERS-CoV, and SARS-CoV) {#Sec17}
-------------------------------------------------------------------------------------------

In this meta-analysis, MERS-CoV was the most predominant causative agent of severe cases among infected pregnant women with a prevalence of 77% with 95% CI \[23--97\], followed by SARS-CoV rated 48% with 95% CI \[[@CR32]--[@CR65]\]. According to our findings, SARS-CoV-2 was the least causative agent of severe cases among the infected pregnant women, which rated 25% with 95% CI \[[@CR7]--[@CR59]\] (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Pooled proportions of severe cases in the overall population of pregnancies infected with coronavirus infection

The effect of SARS-CoV-2, MERS-CoV, and SARS-CoV in pregnant women and their newborns {#Sec18}
-------------------------------------------------------------------------------------

### SARS-CoV-2 {#Sec19}

Out of 39 eligible articles, 25 studies \[[@CR12], [@CR26]--[@CR49]\] reported information on infections caused by SARS-CoV-2 among a total of 1271 pregnancies. The prevalence of SARS-CoV-2 among preterm birth at \< 37 and 34 weeks of gestation was 14.3% and 8.9%, respectively, while 46.2% of pregnant women give birth at \> 37 weeks of gestation. Preeclampsia was reported among 5.7% of pregnant women with COVID-19. pPROM was reported in 8.9%, while the rate of fetal growth restriction was reported in 1.2%. In this study, miscarriage was rated 2.4%. ICU-admitted pregnant women were accounted for 28.5%, while the rate of maternal death was reported in 1.5%. The prevalence of cesarean delivery was 57% (Table [5](#Tab5){ref-type="table"}). Fetal distress was reported among 25%, while the rate of neonatal asphyxia was 1.6%. The prevalence of Apgar score \< 7 at 5 min was 1.4%. The rate of newborns admitted to NICU was 11.6% in which perinatal death was reported among 2.9%. None of the studies reported transmission of SARS-CoV-2 from the mother to the fetus in utero during the follow-up period (Table [5](#Tab5){ref-type="table"}).Table 5Pooled proportions of the different pregnancy and perinatal outcomes identified in the present systematic reviewPregnancy outcomeSARS-CoV-2MERS-CoVSARS-CoVStudy (*n*)Reports (*n*)Pregnancies or neonate (*n*)Pooled  % (95%-CI)Study (*n*)Reports (*n*)Pregnancies or neonate (*n*)Pooled  % (95%-CI)Study (*n*)Reports (*n*)Pregnancies or neonate (*n*)Pooled  % (95%-CI)PTB \< 34 week11616828.9% \[6.1--19.3\]741233.3% \[14.2--38.9\]732512% \[3.6--31.5\]PTB \< 37 week98660214.3% \[9.2--33.2\]70120.0% \[0.0--7.4\]652321.7% \[7.4--44.6\]\>37 week1331768646.2% \[41.5--58.9\]581080% \[44.2--97.8\]751338.5% \[0.0--68.4\]Preeclampsia591595.7% \[3.3--10.1\]21812.5% \[0.0--53.6\]2020% \[0.0--84.7\]pPROM7161798.9% \[5.5--14.6\]2020.0 \[0.0--84.2\]21812.5% \[0.0--53.8\]FGR41861.2% \[0.0--6.3\]4060.0% \[0.0--46.5\]621612.5% \[2.2--38.6\]Miscarriage21412.4% \[0.0--13.5\]--------282138.1% \[18.7--62.5\]ICU admission255318628.5%23.1--54.4\]21333.3% \[1.2--91.3\]2122254.5% \[32.1--76.8\]Maternal death485231.5% \[1.2--9.6\]441040% \[12.5--74.3\]332412.5% \[3.3--32.9\]Cesarean delivery1942674757.0% \[48.9--78.8\]66966.7% \[30.2--93.5\]681650% \[25.6--75.9\]Normal delivery1119266229.0% \[21.4--33.5\]221216.7% \[2.4--48.6\]441822.2% \[6.6--48.7\]Perinatal outcome Fetal distress7145625% \[14.4--39.6\]5000.0% \[0.0--52.3\]541233.3% \[10.1--65.2\] Apgar score \< 771721.4% \[0.0--7.8\]4040.0% \[0.0--60.1\]5050.0% \[0.0--52.3\] Neonatal asphyxia41641.6% \[0.0--8.9\]3030.0% \[0.0--71.4\]4040.0% \[0.060.8\] Admission to NICU486911.6% \[5.4--22.6\]31333.3% \[1.3--84.5\]1010.0% \[0.0--98.5\] Perinatal death854301.2% \[1.0--8.7\]741233.3% \[10.6--65.3\]611010% \[0.0--45.3\] Vertical transmission25012710.0 \[0.0--1.5\]70120.0% \[0.0--26.5\]7070.0% \[0.0--41.6\]*PTB* preterm birth, *pPROM* preterm premature rupture of membranes, *FGR* fetal growth restriction, *ICU* intensive care unit, *NICU* neonatal intensive care unit

### MERS-CoV {#Sec20}

Out of 35 eligible articles, seven studies \[[@CR50]--[@CR56]\] reported information on 12 pregnant women infected with MERS-CoV. The prevalence of preterm birth among pregnant women of \< 34 weeks of gestation was 33.3%, while 80% of pregnant women give birth at \> 37 weeks of gestation. Preeclampsia was observed among 5.7% of pregnant women infected with MERS-CoV. ICU-admitted pregnant women accounted for 33.3%, while the rate of maternal death was reported to be 40%. The prevalence of pregnant women given birth by cesarean was 66.7%, while 16.7% of pregnant women underwent normal delivery. Perinatal death was reported among 33.3% of the newborns, while none of the studies reported fetal distress, apgar score \< 7 at 5 min, neonatal asphyxia, and admission to the neonatal intensive care unit. None of the studies reported transmission of MERS-CoV from the mother to the fetus in utero during the follow-up period (Table [5](#Tab5){ref-type="table"}).

### SARS-CoV {#Sec21}

Out of 35 eligible articles, seven studies \[[@CR57]--[@CR63]\] reported information on 33 pregnant women infected with SARS-CoV. The prevalence of SARS-CoV among preterm birth \< 37 and 34 weeks of gestation was 21.7% and 12%, respectively, while 38.5% of pregnant women give birth at \> 37 weeks of gestation. pPROM was reported in 12.5%, while the rate of fetal growth restriction was reported in 12.5%. Miscarriage was reported among 38.1% of pregnant women. ICU admitted pregnant women were accounted for 54.5%, while the rate of maternal death was reported in 12.5%. The prevalence of pregnant women giving birth by cesarean was 50%, while 22.2% of pregnant women underwent normal delivery. The prevalence of fetal distress and perinatal death was 33.3% and 10%, respectively, while none of the studies reported apgar score \< 7 at 5 min, neonatal asphyxia and admission to the neonatal intensive care unit. None of the studies reported transmission of SARS-CoV from the mother to the fetus in utero during the follow-up period (Table [5](#Tab5){ref-type="table"}).

Heterogeneity and risk of bias {#Sec22}
------------------------------

Subgroup analysis was conducted to justify the cause of heterogeneity. Subgroup analysis of the included studies showed that the possible cause of heterogeneity was a sample size difference, especially in SARS-CoV-2 (*I*^2^ = 94%). The funnel plots suggest a publication bias for some of the study of the parameters (*P* \< 0.02).

Discussion {#Sec23}
==========

Summary of findings {#Sec24}
-------------------

We conducted a systematic review and meta-analysis to provide an overview of the effect of CoV (SARS-CoV-2, MERS-CoV, and SARS-CoV) infection on maternal and perinatal, and the possibility of vertical transmission of the virus from pregnant women to the fetus. The rapidly spreading nature of COVID-19 and previous CoV infections could have a significant effect on human health. Thus, attention should be given to pregnant women, and they should be included in preparedness and response plans. In previous outbreaks, clinicians did not volunteer to treat or vaccinate pregnant women because of concerns for fetal safety \[[@CR64]\]. The pregnant state, with alterations in hormone levels and decreased lung volumes due to a gravid uterus and slightly immunocompromised state may predispose patients to a more rapidly deteriorating clinical course and face a greater risk of harm if they get respiratory infections.

In the current study, the predominant signs and symptoms of hospitalized pregnant women suffering from COVID-19 and other coronavirus infections were viral pneumonia, fever, cough, fatigue, and myalgia. The Centre for disease control listed these symptoms to be the leading clinical feature of patients infected with COVID-19 and other coronaviruses \[[@CR65]\]. The high fever after delivery may have resulted from immunity reduction due to fatigue and blood loss in childbirth, anatomy of female genitalia, sweating during puerperium, and postpartum lactation. Once postpartum fever occurred, obstetricians and gynecologists should follow and perform a differential diagnosis to exclude breast swelling, mastitis, urinary tract infections, common colds, and reproductive tract infections must be focused on. Gastrointestinal symptoms like diarrhea and abdominal pain were also observed in pregnant women with COVID-19 and other coronavirus infections. Gestational diabetes and hypertension were the most common coexisting disorders with a prevalence of 9.6% and 8.5%. More than half of the pregnant women infected with coronaviruses were treated by antiviral and antibiotic therapy.

In our study, the most frequently reported laboratory findings was lymphocytopenia (66.1%), followed by elevated C-reactive protein marker (56.6%), leukopenia (48.3%) and elevated lactate dehydrogenase (34.8%). This is similar to previous studies reporting on COVID-19 and other CoV infections \[[@CR66]--[@CR69]\]. Laboratory findings like leukopenia and lymphocytopenia were helpful to distinguish viral infections from common bacterial infections \[[@CR70]\]. The most common computed tomography imaging features in pregnant women with COVID-19 and non-COVID-19 pneumonia were ground-glass opacity and bilateral pneumonia with a prevalence of 57.9% and 65.8%, respectively. The pathological basis of these changes could be due to inflammatory cell infiltration and interstitial thickening, cell exudation, and hyaline membrane formation. The most common treatment options used were hydroxychloroquine (79.7%), ribavirin (65.2%), oseltamivir (56.5%) and azithromycin (35%) to treat common bacterial pathogens when secondary infections occurred and treat viral pathogens. Among CoV-infected pregnant women, oxygen therapy was 78.8%.

Based on the findings of the present study, higher prevalence of COVID-19 and other CoV was reported among preterm birth \< 37 weeks of gestation. According to some studies report, infection with COVID-19 during pregnancy can cause complications for both the mother and the fetus \[[@CR59], [@CR71]\]. This includes preeclampsia, preterm premature rupture of membranes, fetal growth restriction, and miscarriage. Large numbers of CoV-infected pregnant women with severe cases were admitted to the intensive care unit which even resulted in the death of some mothers. Cesarean deliveries occurred among three-fourths of pregnant women infected with CoV. Regarding the perinatal outcome, fetal distress and neonatal asphyxia were the most commonly reported abnormalities in newborn. The rate of newborns admitted to the neonatal intensive care unit was around 11.3% while 2.2% of them died. MERS-CoV was the predominant causative agent of severe cases in infected pregnant women.

There is much controversy relating to the possibility of in utero transmission of SARS-CoV-2, MERS-CoV, and SARS-CoV. Multiple samples were obtained at the time of labor and delivery to test for the presence of coronavirus by qRT-PCR, including amniotic fluid aspirated from the vagina during labor, cord blood, and segments of the umbilical cord, fetal membranes, and placenta, neonatal nasopharyngeal and throat swabs, gastric aspirate and meconium samples tested negative for the coronaviruses, suggesting there was no evidence of vertical transmission in women who developed COVID-19 and non-COVID-19 coronavirus pneumonia in late pregnancy \[[@CR12], [@CR63], [@CR72]\]. Studies conducted in London \[[@CR73]\] reported a neonate born to a pregnant woman with COVID-19 that tested positive for SARS-CoV-2 in the pharyngeal swab sample 36 h after birth, it was subsequently confirmed that qRT-PCR testing of the placenta and cord blood was negative for SARS-CoV-2, it is believed that the mother or a family member transmitted the infection to the infant through close contact after delivery, not in utero through placenta \[[@CR39], [@CR74]\].

In the current study, the systematic testing procedures for coronavirus infection, including chest radiograph and serial RT-PCR assays with multiple clinical samples did not demonstrate the presence of SARS-CoV-2, MERS-CoV and SARS-CoV in the newborn. CoV antibody tests were performed with mother and newborn sera. In some mothers', sera immunoglobulin G was detected by using serological tests. However, CoV antibodies for IgG, IgM, and IgA were detected in none of the newborn's blood samples \[[@CR55], [@CR75]\]. Therefore, there is no evidence of intrauterine transmission of SARS-CoV-2 and other CoV from mother to newborn infants. This may be due to a very low expression of angiotensin-converting enzyme 2 (ACE2) in early maternal to fetal interface cells \[[@CR76]\]. The virus can be transmitted through close contact or droplets to a new born after birth \[[@CR73]\]. Thus, mothers and their neonates should be taken care of in isolated rooms to prevent neonatal transmission and effective protection measures should be implemented during delivery and postdelivery care to prevent transmission of the virus from mothers to the newborn.

Limitations of the study {#Sec25}
------------------------

Only English articles or reports were considered for this review. The small number of cases in some of the included studies, the study design, and the lack of standardized criteria were the major limitations of this systematic review. Additionally, there is a possibility that some patients were included in more than 1 report, although all authors independently reviewed all the included studies, carefully focusing on the different institutions reporting outcomes. We included case reports and case series, thus facing a higher risk of publication bias, which could affect the estimated outcome. Furthermore, lack of denominator in case series used in this review is the other major factor that affects the estimated outcome. Moreover, when focusing on the outcomes of COVID-19 infection, and particularly perinatal outcomes, reported data are intuitively limited to a very short-term follow-up period and thus infections that occurred proximate to the delivery. This has the potential to overestimate the magnitude of risks such as PTB and underestimate more longitudinal risks such as FGR. In some of the studies, we did not find standardized criteria and timing of delivery of pregnancies affected by CoV infection.

Conclusion {#Sec26}
==========

In general, based on the published data collected, fever, cough, and myalgia were the most common clinical features, while the predominant abnormal laboratory findings reported were lymphocytopenia and C-reactive protein. Bilateral pneumonia and ground-glass opacity were the most common radiological abnormal findings. Oxygen therapy was the most common treatment option used while bacterial coinfection was treated by antibiotics therapy, and viral pathogen was treated by antiviral therapy. Among the coronavirus species, MERS-CoV was the leading cause of severe cases in infected pregnant women. Pregnant women infected with coronaviruses are at increased risk of adverse obstetrical outcomes, compared with the general population. The infection outcome was mainly associated with a relatively higher rate of cesarean delivery, preterm birth, intensive care unit admission, preeclampsia, miscarriage, fetal distress, and perinatal death. None of the studies reported transmission of CoV from the mother to the fetus in utero. This may be due to a very low expression of angiotensin-converting enzyme 2 (ACE2) in early maternal--fetal interface cells as suggested by different experts.

CoV

:   Coronavirus

FGR

:   Fetal growth restriction

ICU

:   Intensive care unit

JBI

:   Joanna Briggs Institute

MERS-CoV

:   Middle East respiratory syndrome coronavirus

NICU

:   Neonatal intensive care unit

pPROM

:   Preterm prelabor rupture of membranes

PTB

:   Preterm birth

RT-PCR

:   Real-time polymerase chain reaction

qRT-PCR

:   Quantitative real-time polymerase chain reaction

SARS-CoV

:   Severe acute respiratory syndrome coronavirus
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